A Bioequivalence Study of Sunitinib Malate Capsules.
A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of Sunitinib Malate Capsules produced by Pfizer and Chia Tai Tianqing Pharmaceutical Group Co., Ltd, respectively.
Gastrointestinal Stromal Tumors|Renal Cell Carcinoma|Pancreatic Neuroendocrine Tumor
DRUG: Sunitinib malate capsules generic product|DRUG: Sunitinib malate capsules reference product
Maximum plasma concentration (Cmax), Maximum plasma concentration, Before administration and 2, 4, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96, 120, 168 hours after administration.|Time to maximum concentration (Tmax), Time to reach maximum concentration after drug administration, Before administration and 2, 4, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96, 120, 168 hours after administration.|Area under the drug-time curve (AUC), Area under the drug-time curve, Before administration and 2, 4, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96, 120, 168 hours after administration.|Apparent terminal elimination half-life (t1/2), Apparent terminal elimination half-life (t1/2), Before administration and 2, 4, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96, 120, 168 hours after administration.|Apparent volume of distribution (Vd/F), Apparent volume of distribution, Before administration and 2, 4, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96, 120, 168 hours after administration.|Clearance rate (CL/F), Clearance rate, Before administration and 2, 4, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96, 120, 168 hours after administration.|Apparent terminal elimination rate constant (Î»z), Apparent terminal elimination rate constant, Before administration and 2, 4, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96, 120, 168 hours after administration.|Relative bioavailability (F), Relative bioavailability (F) of the tested product to reference product, Before administration and 2, 4, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96, 120, 168 hours after administration.
Incidence of adverse events (AE), Incidence of adverse events (AE) evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) V5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.|Severity of adverse events (AE), Severity of adverse events (AE) evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) v5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.|Proportion of subjects with abnormal blood biochemistry results, The proportion of subjects with abnormal blood biochemistry results evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) v5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.|Proportion of subjects with abnormal blood routine, The proportion of subjects with abnormal blood routine results evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) v5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.|Proportion of subjects with abnormal urinalysis results, The proportion of subjects with abnormal urinalysis results evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) v5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.|Proportion of subjects with abnormal coagulation function, The proportion of subjects with abnormal coagulation function evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) v5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.|Proportion of subjects with abnormal thyroid function, The proportion of subjects with abnormal thyroid function evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) v5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.|Proportion of subjects with abnormal blood pressure, The proportion of subjects with abnormal blood pressure evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) v5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.|Proportion of subjects with abnormal pulse, The proportion of subjects with abnormal pulse evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) v5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.|Proportion of subjects with abnormal body temperature, The proportion of subjects with abnormal body temperature evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) v5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.|Proportion of subjects with abnormal 12-lead electrocardiogram (ECG), The proportion of subjects with abnormal 12-lead ECG evaluated in accordance with the National Cancer Institute's Common Toxicity Criteria (NCI CTC) v5.0., From the date of randomization until the date of withdrawal from the study for any reason. Assessed up to 40 days.
A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of Sunitinib Malate Capsules produced by Pfizer and Chia Tai Tianqing Pharmaceutical Group Co., Ltd, respectively.